Logo Medical XPRT
Companies
Products
Services
Software
Training
Applications
Sign in
List your business

Advertising options
  1. Home
  2. News
  3. surgery infection
Show results for
Products
Services
Software
Training
Applications

Companies

News
Articles
Books
Downloads
Videos

Refine by
Date

  • Older

Surgery Infection Articles & Analysis

38 news found

Infection Control Resources to Detect Klebsiella and Other Pathogens in Healthcare Environments

Infection Control Resources to Detect Klebsiella and Other Pathogens in Healthcare Environments

Klebsiella is described by the Centers for Disease Control and Prevention (CDC) as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. Klebsiella are normally found in the human intestines (where they do not cause disease), and also in human ...

ByCochrane & Associates, LLC


Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Comparison of the Rapid Bactericidal Efficacy of Commercially Available Surgical Solutions

Introduction Intraoperative irrigation is a commonly used method aimed at reducing microbial burden by removing tissue debris, metabolic waste, and tissue exudate from the surgical field prior to site closure.1 With the absence of universally established standard of care and robust clinical data, the selection of appropriate irrigation solution remains a topic of debate. Isotonic saline has ...

BySanara MedTech Inc.


Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico

Infection Control Resources to Identify Klebsiella and Other Pathogens in Healthcare Settings throughout Puerto Rico

The Centers for Disease Control and Prevention (CDC) describes Klebsiella as a type of gram-negative bacteria that can cause different types of healthcare-associated infections (HAIs). These include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis. The agency warns Klebsiella bacteria have increasingly developed antimicrobial resistance, most recently to the ...

ByCochrane & Associates, LLC


Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens

Infection Control Resources to Mitigate Patient Exposure Risks to Klebsiella and Other Pathogens

An article published last year in Emerging Infectious Diseases detailed a notable increase of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in New York City during 2021 through June of 2022. The data for the study came from a large public healthcare system in New York City that serves more than 1.2 million people each year. The Centers for Disease Control and Prevention (CDC) ...

ByCochrane & Associates, LLC


Klebsiella in Healthcare Settings Discussed in New Online Video

Klebsiella in Healthcare Settings Discussed in New Online Video

The IAQ Video Network and Cochrane & Associates announced the release of their latest educational video today. Their newest production discusses Klebsiella, a type of gram-negative bacteria that can cause various healthcare-associated infections (HAIs). “HAIs due to Klebsiella can include pneumonia, bloodstream infections, wound or surgical site infections, and meningitis,” said ...

ByCochrane & Associates, LLC


Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation

Caresyntax and Sheba ARC Sign Agreement to Develop the Future Model for Surgical Innovation

Caresyntax, the leading vendor-neutral enterprise surgical data and intelligence platform designed to make surgery smarter and safer by converging AI-powered software, devices, and clinical services, today announced a partnership with ARC (Accelerate, Redesign, Collaborate) Sheba’s Global Innovation platform to establish and replicate the ARC Surgical Innovation Model using ...

ByCaresyntax


XF-73 Nasal Phase 3 development plans finalised

XF-73 Nasal Phase 3 development plans finalised

After a detailed review, the Company has decided that the Phase 3 programme should consist of two Phase 3 studies including patients in two well-defined surgery models. One study will be in breast surgery as a model for general surgery and the other will be in expedited orthopedic surgery as a model of orthopedic ...

ByDestiny Pharma plc


7 December 2022 - FDA/CDC highlight need for infection preventions

7 December 2022 - FDA/CDC highlight need for infection preventions

Destiny Pharma attended the discussion and was very pleased that the meeting reinforced the Company’s conviction in infection prevention as a key component in the management of serious hospital-acquired infections. ...

ByDestiny Pharma plc


XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

XF-73 Dermal infection project advances into clinically enabling safety study with US Government’s NIAID

Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life-threatening infections, is pleased to announce the commencement of an Investigational New Drug (IND) enabling safety study with its novel XF-73 Dermal formulation. This study is the second of two planned preclinical safety studies of the XF-73 ...

ByDestiny Pharma plc


Differences Between Spinal Blocks & Epidurals

Differences Between Spinal Blocks & Epidurals

Remember that many of these risks are carried with any surgery, such as infection, though when dealing with the spine, greater ramifications can result from complications. Infection: Many patients self-administer medication via injection, so it’s not just medical professionals who are at the risk of operator error with injections. ...

ByMilestone Scientific, Inc.


Ondine reports successful US Phase 2 trial data

Ondine reports successful US Phase 2 trial data

aureus is the primary pathogen associated with surgical site infections (SSIs).[i] No reportable adverse events. Ondine Biomedical Inc. ...

ByOndine Biomedical Inc


Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

Nature publication: Ondine’s therapy suppresses SARS2 in COVID-19 patients

The Toronto-based research reports a decrease of viral infectivity of 90% of SARS-CoV-2 patient samples using Ondine’s nasal antimicrobial photodynamic disinfection (aPDT), with 70% of patient samples completely inactivated from a single 5-minute treatment. The nose is the primary location for SARS-CoV-2 entry and it has a central role in transmission and disease severity. The Journal ...

ByOndine Biomedical Inc


Ondine completes enrollment for US Phase II nasal photodisinfection trial

Ondine completes enrollment for US Phase II nasal photodisinfection trial

Recruited patients undergo a pre-surgery nasal culture to determine the prevalence of Staphylococcus aureus, the main cause of surgical site infections. ...

ByOndine Biomedical Inc


Caresyntax & Intel Collaborate to Address Surgical Staffing Shortage

Caresyntax & Intel Collaborate to Address Surgical Staffing Shortage

Combining capabilities to develop breakthrough technologies for transforming surgery. Hospitals and Surgery Centers face many challenges in surgery as they work to recover from COVID. Directors of Perioperative Services, Surgeons, OR Staff and OR managers are facing high levels of stress with maintaining quality patient care, increasing surgical case volume from backlogs, while at the same time ...

ByCaresyntax


PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

PolyActiva to Present Positive Clinical Trial Results at the 2022 American Glaucoma Society Annual Meeting

The second product is a Levofloxacin SR Ocular Implant, an antibiotic-based ocular implant, being developed as a treatment to reduce the risk of infection after cataract surgery. PolyActiva is based in Melbourne, Australia, and has secured venture capital funding from Brandon Capital’s Medical Research Commercialisation Fund (MRCF) and Yuuwa Capital. ...

ByPolyActiva Pty Ltd.


Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract

Imbed’s Microlyte Matrix Added to VA’S IDIQ Contract

Imbed Biosciences Inc. (Imbed), a developer of next-generation therapies for tissue repair, and Spartan Medical, a veteran-owned Federal Contractor with fourteen years of flawless performance, jointly announced today that Imbed’s Microlyte® Matrix wound dressing portfolio has been added to Spartan Medical’s VA IDIQ Contract with the U.S. Department of Veteran Affairs (VA). The ...

ByImbed Biosciences


CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

CytoSorbents Appoints Daniel Wendt, MD, PhD, MHBA, FECTS as Vice President, Medical Affairs Cardiovascular

Wendt serves as Co-director of the Thoracic and Cardiovascular Surgery Clinic, West German Heart and Vascular Center in Essen, Germany and is Professor of Cardiac Surgery at Essen University Medical School. ...

ByCytoSorbents Corporation


Versius surgical robot used for first time in an Italian public hospital

Versius surgical robot used for first time in an Italian public hospital

Operating using Versius has enabled us to perform more keyhole surgery, allowing us to offer benefits such as faster recovery times, less time in hospital and reduced risk of infection to our patients.” At Policlinico di Milano, Versius will be used to perform a range of procedures including cholecystectomy, lower anterior resection and pulmonary resection ...

ByCMR Surgical Ltd


Takeover of terraplasma medical GmbH by the Viromed Group

Takeover of terraplasma medical GmbH by the Viromed Group

It can revolutionize, supplement and in some cases even replace conventional treatment methods in medical technology, e.g., in surgery to prevent infections in post-operative wounds. In nursing service, cold atmospheric plasma offers a therapeutic option to treat chronic and hard to heal wounds. ...

Byterraplasma medical GmbH


CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

CytoSorbents Announces Availability of Preliminary Data Abstracts from Two Endocarditis Studies, including the REMOVE study, to be Presented at the EACTS Conference

A summary of the abstracts are as follows: The REMOVE (“Revealing Mechanisms and Investigating Efficiency Of Hemoadsorption for Prevention of Vasodilatory Shock in Cardiac Surgery Patients with Infective Endocarditis“) investigator initiated randomized, controlled trial enrolled 288 patients with documented infective endocarditis ...

ByCytoSorbents Corporation

  • Previous
  • Next
Need help finding the right suppliers?Try XPRT Sourcing. Let the XPRTs do the work for you
Back to top
About Medical XPRT

Medical XPRT is a global marketplace with solutions and suppliers for the medical sector, with product catalogs, articles, industry events, publications & more.

Channels

Solutions

  • Medical Equipment & Supplies
  • Medical Software
  • Medical Training Courses
  • Medical Industry Services
  • Medical Product Applications

Latest

  • Medical Industry News
  • Medical Industry Events

Publications

  • Medical Industry Articles & Case Studies
  • Medical Industry Books and Publications
  • Medical Industry Journals and Magazines
  • Medical Industry Downloads
  • Medical Industry Videos

Companies

  • Medical Industry Suppliers & Manufacturers

  • FAQs
  • Company sitemap
  • Category sitemap
Medical XPRT is part of XPRT Media All Rights Reserved.
Terms
Privacy
  • Medical XPRT RSS List
Our sites:
Environmental XPRT
Agriculture XPRT
Energy XPRT
XPRT